Merck vs Pfizer — CEO Pay Comparison
Rob Davis (Merck) earns $0 more in total compensation than Albert Bourla (Pfizer).
| Metric | MerckMRK | PfizerPFE |
|---|---|---|
| CEO | Rob Davis | Albert Bourla |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Total Compensation | $12.0M | $12.0M |
| Base Salary | $1.2M | $1.2M |
| Stock Awards | $6.0M | $6.0M |
| Option Awards | $1.4M | $1.4M |
| Non-Equity Incentive | $1.8M | $1.8M |
| Pay-for-Performance Grade | B (71/100) | C (61/100) |
| CEO-Worker Pay Ratio | 120:1 | 120:1 |
| Median Worker Pay | $100K | $100K |
| Say-on-Pay Approval | 94.6% | 86.8% |
| 3yr Total Shareholder Return | +11.7% | -4.2% |
| Revenue | $60.1B | $58.5B |
| Market Cap | $280.0B | $160.0B |
| Employees | 69,000 | 88,000 |
Analysis
Rob Davis (Merck) earns $12.0M in total compensation, while Albert Bourla (Pfizer) earns $12.0M.
On pay-for-performance alignment, Merck scores B (71/100) while Pfizer scores C (61/100). Merck's CEO compensation is better aligned with company performance.
Merck's CEO-to-worker pay ratio is 120:1 compared to Pfizer's 120:1. Shareholders approved CEO pay at 94.6% (Merck) and 86.8% (Pfizer).